VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 36.36 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $183.000 thousand which missed the analyst consensus estimate of $223.333 thousand by 18.06 percent. This is a 34.10 percent decrease over sales of $277.700 thousand the same period last year.